The role of adipokines in hypertension and cardiovascular disease

Current Hypertension Reviews

Volumn 3, Issue 3, 2007, Pages 208-215

  Wilson, Andrew M ^a   Ryan, Marno C ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Atherosclerosis; Cardiovascular disease; Diabetes; Hypertension; Inflammation; Obesity

Indexed keywords

ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSINOGEN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIN 1; GEMFIBROZIL; GLITAZONE DERIVATIVE; INSULIN; INTERLEUKIN 1; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; SOMATOSTATIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASOACTIVE AGENT;

ADIPOCYTE; ARTERY INJURY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CELL SECRETION; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; ENDOCRINE CELL; ENDOTHELIAL DYSFUNCTION; GENETIC TRANSFECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IN VITRO STUDY; INFLAMMATION; INSULIN INFUSION; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; RISK FACTOR; VEIN THROMBOSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 34547849471     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340207781386738     Document Type: Review

References (112)

1. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stróke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999; 22(7): 1077-83.
2. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162(16): 1867-72.
3. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997; 100(5): 1166-73.
4. Ramos EJ, Xu Y, Romanova I, et al. Is obesity an inflammatory disease? Surgery 2003; 134(2): 329-35.
5. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW, Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341(15): 1097-105.
6. Rea TD, Heckbert SR, Kaplan RC, et al. Body mass index and the risk of recurrent coronary events following acute myocardial infarction. Am J Cardiol. 2001; 88(5): 467-72.
7. Abbasi F, Brown BW, Jr., Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40(5): 937-43.
8. Chambers JC, Eda S, Bassett P, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104(2): 145-50.
9. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104(25): 3052-6.
10. Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246(4): 409-18.
11. Soderberg S, Ahren B, Stegmayr B, et al. Leptin is a risk marker for first-ever hemorrhagic-stroke in a population-based cohort. Stroke 1999; 30(2): 328-37.
12. Bodary PF, Westriek RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. Jama 2002; 287(13): 1706-9.
13. Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999; 892: 25-44.
14. Wauters M, Considine RV, Yudkin JS, Peiffer F, De Leeuw I, Van Gaal LF. Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. Horm Metab Res 2003; 35(2): 92-6.
15. Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of Flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86(2): 207-10.
16. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101(16): 1899-906.
17. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76(2): 301-14.
18. Behrendt D. Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002; 90(10C): 40L-8L.
19. Brook RD, Bard RL, Rubenfire M, Ridker PM, Rajagopalan S. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 2001; 88(11): 1264-9.
20. Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt GD. The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86(11): 5491-7.
21. Ramsay JE, Ferrell WR, Crawford L, Wallace AM, Greer IA, Sattar N. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab 2002; 87(9): 4231-7.
22. Raitakari M, Ilvonen T, Ahotupa M, et al. Weight reduction with very-low-caloric diet and endothelial function in overweight adults: role of plasma glucose. Arterioscler Thromb Vasc Biol 2004; 24(1): 124-8.
23. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Chayama K, Oshima T. Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals, and patients with essential hypertension. Am J Hypertens 2001; 14(10): 1038-45.
24. Bohlen HG, Nase GP. Obesity lowers hyperglycemic threshold for impaired in vivo endothelial nitric oxide function. Am J Physiol Heart Circ Physiol 2002; 283(1): H391-7.
25. Traupe T, D'Uscio LV, Muenter K, Morawietz H, Vetter W, Barton M. Effects of obesity on endothelium-dependent reactivity during acute nitric oxide synthase inhibition: modulatory role of endothelin. Clin Sci (Lond) 2002; 103 Suppl 48: 13S-5S.
26. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148(2): 209-14.
27. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000; 98(5): 531-5.
28. Holmlund A, Hulthe J, Millgard J, Sirabi M, Kahan T, Lind L. Soluble intercellular adhesion molecule-1 is related to endothelial vasodilatory function in healthy individuals. Atherosclerosis 2002; 165(2): 271-6.
29. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 2002; 105(22): 2600-4.
30. Wong M, Toh L, Wilson A, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003; 48(1): 81-9.
31. Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88(2): 112-7.
32. Leibel RL, Chung WK, Chua SC, Jr. The molecular genetics of rodent single gene obesities. J Biol Chem 1997; 272(51): 31937-40.
33. Rosenbaum M, Leibel RL. The role of leptin in human physiology. N Engl J Med 1999; 341(12): 913-5.
34. Considine RV, Considine EL, Williams CJ, Hyde TM, Caro JF. The hypothalamic leptin receptor in humans: identification of incidental sequence-polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes 1996; 45(7): 992-4.
35. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334(5): 292-5.
36. Zakrzewska KE, Cusin I, Sainsbury A, Rohner-Jeanrenaud F, Jeanrenaud B. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 1997; 46(4): 717-9.
37. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin-deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387(6636): 903-8.
38. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341(12): 879-84.
39. Rosenbaum M, Nicolson M, Hirsch J, Murphy E, Chu F, Leibel. RL. Effects of weight change on plasma leptin concentrations and energy expenditure. J Clin Endocrinol Metab 1997; 82(11): 3647-54.
40. Mark AL, Correia ML, Rahmouni K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002; 20(7): 1245-50.
41. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108(10): 1533-40.
42. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281(5383): 1683-6.
43. Murad A, Nath AK, Cha ST, Demir E, Flores-Riveros J, Sierra-Honigmann MR. Leptin is an autocrine/paracrine regulator of wound healing. FASEB J 2003; 17(13): 1895-7.
44. Ambrosini G, Nath AK, Sierra-Honigmann MR, Flores-Riveros J. Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J Biol Chem 2002; 277(37): 34601-9.
45. Winters B, Mo Z, Brooks-Asplund E, et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese Lep(ob)) mice. J Appl Physiol 2000; 89(6): 2382-90.
46. Mastronardi CA, Yu WH, McCann SM. Resting and circadian release of nitric oxide is controlled by leptin in male rats. Proc Natl Acad Sci U S A 2002; 99(8): 5721-6.
47. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003; 170(1): 21-9.
48. Quehenberger P, Exner M, Sunder-Plassmann R, et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002; 90(6): 711-8.
49. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13(10): 1231-8.
50. Singhal A, Farooqi IS, Cole TJ, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 2002; 106(15): 1919-24.
51. Vaya A, Mira Y, Ferrando F, et al. Hyperlipidaemia and venous. thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002; 118(1): 255-9.
52. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinul Invest 2002; 25(10): 899-904.
53. Gurm HS, Brennan DM, Booth J, Tcheng JE, Lincoff AM, Topol EJ. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol 2002; 90(1): 42-5.
54. Baynes JW. Chemical modification of proteins by lipids in diabetes. Clin Chem Lab Med 2003; 41(9): 1159-65.
55. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48(1): 1-9.
56. Maruyama I, Nakata M, Yamaji K. Effect of leptin in platelet and endothelial cells. Obesity and arterial thrombosis. Ann N Y Acad Sci 2000; 902: 315-9.
57. Barba G, Russo O, Siani A, et al. Plasma leptin and blood pressure in men: graded association independent of body mass and fat pattern. Obes Res 2003; 11(1): 160-6.
58. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, Chayama K. Leptin causes vasodilation in humans. Hypertens Res 2002; 25(2): 161-5.
59. Lembo G, Vecchione C, Fratta L, et al. Leptin induces direct vasodilation through distinct endothelial mechanism. Diabetes 2000; 49(2): 293-7.
60. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002; 51(1): 168-73.
61. Vecchione C, Aretini A, Maffei A, et al. Cooperation between insulin and leptin in the modulation of vascular tone. Hypertension 2003; 42(2): 166-70.
62. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31(1 Pt 2): 409-14.
63. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000; 105(9): 1243-52.
64. Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz J Med Biol Res 2000; 33(6): 605-18.
65. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002; 39(2 Pt 2): 496-501.
66. Balletshofer BM, Rittig K, Stock J, et al. Insulin resistant young subjects at risk of accelerated atherosclerosis exhibit a marked reduction in peripheral endothelial function early in life but not differences in intima-media thickness. Atherosclerosis 2003; 171(2): 303-9.
67. Suzuki M, Takamisawa I, Suzuki K, et al. Close association of endothelial dysfunction with insulin resistance and carotid wall thickening in hypertension. Am J Hypertens 2004; 17(3): 228-32.
68. Hamdy O, Ledbury S, Mullooly C, et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26(7): 2119-25.
69. Avogaro A, Miola M, Favaro A, et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest 2001; 31(7): 603-9.
70. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003; 52(2): 173-80.
71. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in human. J Clin Invest 1994; 94(6): 2511-5.
72. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin-mediated vasodilation and glucose uptake are functionally linked in humans. Hypertension 1999; 33(1 Pt 2): 554-8.
73. Yki-Jarvinen H, Utriainen T. Ensulin-induced vasodilatation: physiology or pharmacology? Diabetologia 1998; 41(4): 369-79.
74. Petrie JR, Cleland SJ, Ueda S, Elliott HL, Connell JM. Insulin-mediated vasodilation and forearm plethysmography: physiology not pharmacology. Diabetologia, 1999; 42(11): 1376.
75. Steinberg HO, Baron AD. Insulin-mediated vasodilation: why one's physiology could be the other's pharmacology. Diabetologia 1999; 42(4): 493-5.
76. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45(5): 623-34.
77. Campia U, Sullivan G, Bryant MB, Waclawiw MA, Quon MJ, Panza JA. Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. Am J Physiol Heart Circ Physiol 2004; 286(1): H76-82.
78. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105(5): 576-82.
79. Ueda S, Petrie JR, Cleland SJ, Elliott HL, Connell JM. The vasodilating effect of insulin is dependent on local glucose uptake: a double blind, placebo-controlled study. J Clin Endocrinol Metab 1998; 83(6): 2126-31.
80. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol 1998; 25(3-4): 175-84.
81. Reed AS, Charkoudian N, Vella A, Shah P, Rizza RA, Joyner MJ. Forearm vascular control during acute hyperglycemia in healthy humans. Am J Physiol Endocrinol Metab 2004; 286(3): E472-80.
82. Frank HJ, Levin ER, Hu RM, Pedram A. Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells. Endocrinology 1993; 133(3): 1092-7.
83. Hu RM, Levin ER, Pedram A, Frank HJ. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993; 42(2): 351-8.
84. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000; 49(7): 1231-8.
85. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002; 51(12): 3517-23.
86. Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes Relat Metab Disord 2002; 26 Suppl 2: S28-38.
87. Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation 2002; 106(15): 1904-5.
88. Schafer K, Halle M, Goeschen C, et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 2004; 24(1): 112-7.
89. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001; 88(9): 954-60.
90. Kingwell BA, Gatzka CD. Arterial stiffness and prediction of cardiovascular risk. J Hypertens 2002; 20(12): 2337-40.
91. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001; 25(6): 805-10.
92. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595-9.
93. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100(25): 2473-6.
94. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103(8): 1057-63.
95. Matsuda M, Shimomura, I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277(40): 37487-91.
96. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106(22): 2767-70.
97. Ouchi N, Ohishi M, Kibara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42(3): 231-4.
98. Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89(2): 765-9.
99. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102(l1): 1296-301.
100. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004; 12(2): 180-6.
101. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50(9): 2094-9.
102. Hall JE, Louis K. Dahl Memorial Lecture. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994; 23(3): 381-94.
103. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321(4): 225-36.
104. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283(14): 1829-36.
105. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105(21): 2462-4.
106. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91(11): 988-98.
107. Agnoletti L, Curello S, Bachetti T, et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 1999; 100(19): 1983-91.
108. Fichtlscherer S, Rossig L, Breuer S, Vasa M, Dimmeler S, Zeiher AM. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001; 104(25): 3023-5.
109. Muller-Ehmsen J, Schwinger RH. TNF and congestive heart failure: therapeutic possibilities. Expert Opin Ther Targets 2004; 8(3): 203-9.
110. Zhang P, Reisin E. Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens 2000; 13(12): 1308-14.
111. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 1997; 10(5 Pt 2): 49S-55S.
112. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002; 39(1): 1-11.